3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myeloproliferative Disorders
3
Primary Myelofibrosis
1
Blast Crisis
1
Interventions
Cyclophosphamide
14
fludarabine phosphate
11
Cyclosporine
11
Antilymphocyte Serum
10
Mycophenolic Acid
9
ruxolitinib
8
Radiotherapy
6
Cord Blood Stem Cell Transplantation
6
Busulfan
6
fludarabine
5
Whole-Body Irradiation
5
Tacrolimus
5
Methylprednisolone
5
Azacitidine
5
Stem Cell Transplantation
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
Melphalan
4
Filgrastim
4
thymoglobulin
3
parsaclisib
3
Sirolimus
3
Nivolumab
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
abiraterone
2
Tretinoin
2
Surveys and Questionnaires
2
Sunitinib
2
Rituximab
2
Moxifloxacin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Primary Myelofibrosis
×
fedratinib
×
Clear all
NCT03755518
2024-12-12
FREEDOM
Celgene
Phase 3
Terminated
38 enrolled
23 charts